For research use only. Not for therapeutic Use.
ML395 (Cat.No:I008108), also known as VU0468809, is a potent PLD2 inhibitor. ML39 showed potent antiviral activity. ML395 (VU0468809), a potent, >80-fold PLD2 selective allosteric inhibitor (cellular PLD1, IC50 >30,000 nM; cellular PLD2, IC50 =360 nM). Moreover, ML395 possesses an attractive in vitro DMPK profile, improved physiochemical properties, ancillary pharmacology (Eurofins Panel) cleaner than any other reported PLD inhibitor, and has been found to possess interesting activity as an antiviral agent in cellular assays against a range of influenza strains (H1, H3, H5 and H7).
| Catalog Number | I008108 |
| CAS Number | 1638957-17-1 |
| Synonyms | ML395; ML-395; ML 395; VU0468809; VU-0468809; VU 0468809.;N-(2-(4-oxo-1-(pyridin-3-ylmethyl)-1,3,8-triazaspiro[4.5]decan-8-yl)ethyl)-2-naphthamide |
| Molecular Formula | C26H29N5O2 |
| Purity | ≥95% |
| Target | PLD2 inhibitor |
| Solubility | Soluble in DMSO |
| Storage | Store at -20°C |
| InChI | InChI=1S/C26H29N5O2/c32-24(23-8-7-21-5-1-2-6-22(21)16-23)28-12-15-30-13-9-26(10-14-30)25(33)29-19-31(26)18-20-4-3-11-27-17-20/h1-8,11,16-17H,9-10,12-15,18-19H2,(H,28,32)(H,29,33) |
| InChIKey | VBJYNYMKFQGJCH-UHFFFAOYSA-N |
| SMILES | O=C(NCN1CC2=CC=CN=C2)C31CCN(CCNC(C4=CC(C=CC=C5)=C5C=C4)=O)CC3 |
| Reference | 1:ChemMedChem. 2014 Dec;9(12):2633-7. doi: 10.1002/cmdc.201402333. Epub 2014 Sep 10. Discovery of a highly selective PLD2 inhibitor (ML395): a new probe with improved physiochemical properties and broad-spectrum antiviral activity against influenza strains.O/’Reilly MC,Oguin TH 3rd,Scott SA,Thomas PG,Locuson CW,Morrison RD,Daniels JS,Brown HA,Lindsley CW, PMID: 25210004 PMCID: PMC4535312 DOI: 10.1002/cmdc.201402333 </br><span>Abstract:</span> Further chemical optimization of the halopemide-derived family of dual phospholipase D1/2 (PLD1/2) inhibitors afforded ML395 (VU0468809), a potent, >80-fold PLD2 selective allosteric inhibitor (cellular PLD1, IC50 >30,000 nM; cellular PLD2, IC50 =360 nM). Moreover, ML395 possesses an attractive in vitro DMPK profile, improved physiochemical properties, ancillary pharmacology (Eurofins Panel) cleaner than any other reported PLD inhibitor, and has been found to possess interesting activity as an antiviral agent in cellular assays against a range of influenza strains (H1, H3, H5 and H7).© 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. |
